Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1111 to 1125 of 1305 results for long term conditions

  1. Safety and efficacy of botulinum toxin:- What is the safety and efficacy of botulinum toxin compared with (a) usual care, (b) antimuscarinics and (c) augmentation cystoplasty in people with neurogenic lower urinary tract dysfunction?

    intradetrusor injections of botulinum toxin type A have long-term efficacy. The efficacy in terms of...

    Research recommendation
    Published
    9 June 2015

  2. What are the service and service user characteristics of highly specialist and longer-term high-dependency rehabilitation units that are associated with better outcomes?

    service and service user characteristics of highly specialist and longer-term high-dependency rehabilitation units that are associated...

    Research recommendation
    Published
    26 October 2020

  3. Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)

    Evidence-based recommendations on vedolizumab (Entyvio) for previously treated moderately to severely active Crohn’s disease in adults.

    Technology appraisal guidance
    Published
    26 August 2015
    View recommendations

    Sections for TA352

  4. Insertion of a magnetic bead band for faecal incontinence (HTG336)

    Evidence-based recommendations on insertion of a magnetic-bead band for faecal incontinence. This involves placing a ring of magnetic beads into a tunnel made around the anus to prevent incontinence.

    HealthTech guidance
    Published
    27 March 2014
    View recommendations

    Sections for HTG336

  5. Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen (TA316)

    Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic hormone-relapsed prostate cancer in adults who have had treatment with docetaxel-containing chemotherapy.

    Technology appraisal guidance
    Published
    23 July 2014
    View recommendations

    Sections for TA316

  6. Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)

    Evidence-based recommendations on rifaximin (Targaxan) for preventing episodes of hepatic encephalopathy in adults.

    Technology appraisal guidance
    Published
    25 March 2015
    View recommendations

    Sections for TA337

  7. Cardiac rehabilitation:- Is an 8-week, comprehensive, multidisciplinary, cardiac rehabilitation service more clinically and cost effective for managing stable angina than current clinical practice?

    rehabilitation programmes are an established treatment strategy for certain heart conditions, such as for people who have had a heart...

    Research recommendation
    Published
    9 June 2015

  8. Granulox for managing chronic non-healing wounds (MIB296)

    NICE has developed a medtech innovation briefing (MIB) on Granulox for managing chronic non-healing wounds .

    Medtech innovation briefing
    Published
    10 May 2022

  9. The PressureWire fractional flow reserve measurement system for coronary artery disease (MIB2)

    NICE has developed a Medtech Innovation Briefing (MIB) on the PressureWire fractional flow reserve measurement system

    Medtech innovation briefing
    Published
    4 February 2014

  10. Emotional and psychological support and interventions:- What emotional support do children and young people with life-limiting conditions and their parents or carers need, and how would they like these needs to be addressed?

    research recommendation

    Research recommendation
    Published
    1 November 2017

  11. MRI-based technologies for assessing non-alcoholic fatty liver disease (HTG655)

    Evidence-based recommendations on MRI-based technologies for assessing non-alcoholic fatty liver disease.

    HealthTech guidance
    Published
    12 January 2023
    View recommendations

    Sections for HTG655

  12. Health Technology Assessment Innovation Laboratory (HTA Lab)

    NICE's HTA Lab enables us to develop creative solutions to complex problems in health technology assessment.

  13. Blood pressure targets: What is the clinical and cost effectiveness of a lower blood pressure treatment target relative to the standard blood pressure treatment target for people with aneurysmal subarachnoid haemorrhage?

    other conditions after discharge from hospital. Full details of the evidence and the committee's discussion are in evidence review Q:...

    Research recommendation
    Published
    12 December 2022

  14. Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)

    Evidence-based recommendations on cetuximab (Erbitux) and panitumumab (Vectibix) for previously untreated RAS wild-type metastatic colorectal cancer in adults.

    Technology appraisal guidance
    Last updated
    25 September 2017
    View recommendations

    Sections for TA439

  15. Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (TA209)

    Evidence-based recommendations on imatinib for treating unresectable or metastatic gastrointestinal stromal tumours in adults.

    Technology appraisal guidance
    Published
    24 November 2010
    View recommendations

    Sections for TA209